Insight

Naveen Pemmaraju: Ph2 CLIA with or without sorafenib for upfront AML therapy

Naveen Pemmaraju, the Executive Director of Cancer Medicine at the MD Anderson Cancer Center, recently tweeted:

“Brand new paper alert from our group Ph2 CLIA with or without sorafenib for upfront AML therapy led by Tapan Kadia, Hagop Kantarjian, Gautam Borthakur, Naval Daver, Naveen Pemmaraju, Nitin Jain and Musa Yilmaz.”

For the article click here.
Source: Naveen Pemmaraju/Twitter

Naveen Pemmaraju: Ph2 CLIA with or without sorafenib for upfront AML therapy.

cancer Gautam Borthakur Hagop Kantarjian Musa Yilmaz Naval Daver Naveen Pemmaraju Nitin Jain OncoDaily Oncology Research sorafenib Tapan Kadia Twitter